- Astex Pharma presented 9/27 at Jefferies conference. Click here for calendar of other webcasts and catalysts with links to my notes and find more detailed company and pipeline info on ASTX research page.
- pipeline slide (see below) - programs listed in order or prioritization after merger
- focus on molecularly-targeted small molecules, primarily in oncology space
- HSP90 - phase 1 just about complete. we've seen very early indications of clinical activity, including 1 SD and 1 PR among 4 GIST patients
- Montigen - in process of forming new public spinout company (more info here).
- no questions asked...
RSS Feed
